These observations support earlier histologic findings, demonstrating expansion of the CD8+ T-cell population and closer proximity between cytotoxic CD8+ TILs and tumor cells in the TME after CAN-2409 treatment in patients with NSCLC, consistent with improved antitumor immunity. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.